Determining predominating histologic component in malignant mixed müllerian tumors: Is it worth it?

International Journal of Gynecological Cancer

Volumn 18, Issue 4, 2008, Pages 809-812

  Ozguroglu, M ^a,b   Bilici, A ^a   Ilvan, S ^a   Turna, H ^a   Atalay, B ^a   Mandel, N ^a   Sahinler I ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Carcinomatous and sarcomatous component; Malignant mixed m llerian tumors

Indexed keywords

CARBOPLATIN; CISPLATIN; IFOSFAMIDE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DIAGNOSTIC VALUE; ENDOMETRIUM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MIXED MULLERIAN TUMOR; MULTIMODALITY CANCER THERAPY; OVARY; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MIDDLE AGED; MIXED TUMOR, MULLERIAN; NEOPLASM METASTASIS; NEOPLASM STAGING; PLANNING TECHNIQUES; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 47649111084     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01074.x     Document Type: Article

References (21)

1. Dehner L, Norris H, Taylor H. Carcinosarcomas and mesodermal tumors of ovary. Cancer 1971 27 : 207 16.
2. Wei LH, Huang CY, Cheng SP, Chen CA, Hsieh CY. Carcinosarcoma of ovary associated with previous radiotherapy. Int J Gynecol Cancer 2001 11 : 81 4.
3. Arrastia CD, Fruchter RG, Clark M et al. Uterine carcinosarcomas: incidence and trends in management and survival. Gynecol Oncol 1997 65 : 158 63.
4. Morrow C, d'Ablaing G, Brady L, Blessing J, Hreschyshyn M. A clinical and pathologic study of 30 cases of malignant mixed mullerian epithelial and mesenchymal ovarian tumors: a Gynecologic Oncology Group study. Gynecol Oncol 1984 18 : 278 92.
5. Terada KY, Johnson TL, Hopkins M, Roberts JA. Clinicopathologic features of ovarian mixed mesodermal tumors and carcinosarcomas. Gynecol Oncol 1989 32 : 228 32.
6. DiSilvestro PA, Gajewski WH, Ludwig ME, Kourea H, Sung J, Granai CO. Malignant mixed mesodermal tumors of the ovary. Obstet Gynecol 1995 86 : 780 82.
7. Spanos WJ Jr., Peters LJ, Oswald MJ. Patterns of recurrence in malignant mixed mullerian tumor of the uterus. Cancer 1986 57 : 155 59.
8. Sartori E, Bazzurini L, Gadducci A et al. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol Oncol 1997 67 : 70 5.
9. Inthasorn P, Beale P, Dalrymple C, Carter J. Malignant mixed mullerian tumour of the ovary: prognostic factor and response of adjuvant platinum-based chemotherapy. Aust N Z J Obstet Gynaecol 2003 43 : 61 4.
10. Muntz HG, Jones MA, Barbara AG et al. Malignant mixed mullerian tumors of ovary: experience with surgical cytoreduction and combination chemotherapy. Cancer 1995 76 : 1209 13.
11. Sit AS, Price FV, Kelley JL et al. Chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol Oncol 2000 79 : 196 200.
12. Gerszten K, Faul C, Kounelis S, Huang Q, Kelley J, Jones MW. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol 1998 68 : 8 13.
13. Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 2000 88 : 2782 86.
14. Chi DS, Mychalczak B, Saigo PE, Rescigno J, Brown CL. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol 1997 65 : 493 98.
15. Nielsen SN, Podratz KC, Scheithauer BW, O'Brien PC. Clinicopathologic analysis of uterine malignant mixed mullerian tumors. Gynecol Oncol 1989 34 : 372 78.
16. Inthasorn P, Carter J, Valmadre S, Beale P, Russell P, Dalrymple C. Analysis of clinicopathologic factors in malignant mixed Mullerian tumors of the uterine corpus. Int J Gynecol Cancer 2002 12 : 348 53.
17. Pautier P, Genestie C, Rey A et al. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 2000 88 : 1425 31.
18. Iwasa Y, Haga H, Konishi I et al. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients. Cancer 1998 82 : 512 19.
19. Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF. Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol Oncol 2002 85 : 459 63.
20. Bicher A, Levenback C, Silva EG, Burke TW, Morris M, Gershenson DM. Ovarian malignant mixed mullerian tumors treated with platinum-based chemotherapy. Obstet Gynecol 1995 85 : 735 39.
21. Knocke TH, Kucera H, Dorfler D, Pokrajac B, Potter R. Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri. Cancer 1998 83 : 1972 79.